Brown adipose tissue, anthropometric traits, and metabolic profiles in women with normal weight obesity
July 7, 2025 / brown adipose tissue / normal-weight obesity / cardiometabolic risk / body fat percentage / metabolic health
Women with normal-weight obesity (NWO) show significantly lower brown adipose tissue (BAT) vascular density compared to normal-weight women, linking reduced BAT to higher body fat accumulation and increased risk of cardiometabolic dysfunction despite normal BMI.
Astrocytes in Obesity: Brain Cells That Control Metabolism & Cognition
July 7, 2025 / astrocytes / obesity and cognition / brain metabolism / striatum function / obesity treatment
Astrocytes in the brain’s striatum influence both cognition and metabolism in obesity. Modulating their activity in obese mice improved learning and energy regulation, revealing astrocytes as potential therapeutic targets for obesity-related cognitive and metabolic dysfunction.
CagriSema Shows Weight Loss and Metabolic Benefits in REDEFINE Trials for Obesity and Type 2 Diabetes
July 7, 2025 / CagriSema / obesity treatment / type 2 diabetes / metabolic health / weight loss therapy
CagriSema, an investigational combination therapy, demonstrated significant weight loss and improved metabolic markers in patients with obesity and type 2 diabetes in the REDEFINE trials, signaling its promise as a future treatment option for these chronic conditions.
New Wearable Algorithm Improves Fitness Tracking in Obesity
July 3, 2025 / obesity fitness tracking / wearable algorithm / energy expenditure accuracy / smartwatch for obesity / personalized activity monitoring
A new wearable algorithm significantly improves calorie and energy expenditure estimates in individuals with obesity by accounting for differences in gait and metabolism, enhancing accuracy of fitness tracking and offering more inclusive health monitoring tools.
Metabolic differences in male and female muscles may explain diabetes variations
July 7, 2024 / sex differences metabolism / muscle glucose uptake / diabetes risk men women / exercise response diabetes / personalized diabetes prevention
Men and women differ in how their muscles process glucose and fat, influencing diabetes risk and response to exercise. These sex-specific metabolic traits may guide more personalized prevention and treatment strategies for type 2 diabetes.
Metabolome alterations in pediatric metabolically unhealthy obesity are primarily linked to abnormal glucose homeostasis
July 4, 2025 / pediatric obesity / metabolically unhealthy obesity / glucose homeostasis / branched-chain amino acids / childhood metabolic risk
Metabolomic profiling in Asian children revealed that differences between metabolically healthy and unhealthy obesity are mainly linked to impaired glucose homeostasis, identifying biomarkers like branched-chain amino acids and 1,5-anhydroglucitol as potential early indicators of pediatric metabolic dysfunction.
Preventing obesity with an immune-altering gut microbe
July 1, 2025 / gut microbiome obesity / Phascolarctobacterium faecium / immune modulation / probiotic for weight loss / metabolic inflammation
The gut bacterium Phascolarctobacterium faecium reduces obesity-related inflammation and weight gain in mice by boosting anti-inflammatory immune responses. It shows promise as a probiotic or postbiotic therapy for preventing obesity and metabolic disorders.
Cysteine plays key role in weight loss and fat metabolism
July 7, 2025 / cysteine and weight loss / fat metabolism / white to brown fat / caloric restriction metabolism / obesity treatment strategies
Caloric restriction reduces cysteine levels, triggering white-to-brown fat conversion and enhancing fat metabolism. This mechanism, confirmed in humans and animal models, highlights cysteine depletion as a potential target for weight loss therapies beyond simple calorie reduction.
Striatal astrocytes modulate behavioral flexibility and whole-body metabolism in mice
July 7, 2025 / striatal astrocytes / obesity and metabolism / cognitive flexibility / astrocyte activation / brain-gut connection
Striatal astrocytes in the brain regulate both behavioral flexibility and peripheral metabolism. In obese mice, chemogenetic activation of these astrocytes reversed cognitive deficits and improved metabolic function, highlighting a novel neuro-glial link in obesity-related dysfunction.
Predictive values of neck circumference and TyG index on polycystic ovary syndrome with metabolic syndrome
July 5, 2024 / PCOS metabolic syndrome / neck circumference PCOS / TyG index predictor / insulin resistance women / obesity and fertility
Neck circumference (NC) and triglyceride-glucose (TyG) index are effective predictors of polycystic ovary syndrome with metabolic syndrome in reproductive-age women. NC, being simple and cost-effective, offers a practical screening tool for early identification and intervention.
Morphic Medical Announces CE Mark for RESET® Endoscopic Device Therapy
July 7, 2025 / RESET endoscopic therapy / duodenal-jejunal bypass liner / obesity type 2 diabetes / non-surgical weight loss / CE Mark metabolic device
Morphic Medical’s RESET® System, a non-surgical endoscopic duodenal-jejunal bypass liner, has received CE Mark approval. It offers significant weight loss and glycemic improvement in patients with obesity and type 2 diabetes, mimicking metabolic effects of gastric bypass.
Eli Lilly’s 3-step strategy to dominate the $95 billion obesity market
July 7, 2025 / Eli Lilly obesity drugs / tirzepatide weight loss / GLP-1 pill orforglipron / bimagrumab fat muscle / metabolic health innovation
Eli Lilly is leading the obesity drug market with a 3-step strategy: rapid development, more convenient delivery (including pills), and a diverse pipeline targeting fat loss, muscle preservation, and metabolic regulation—positioning it to capture 50% of a $95B market.
Skye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a Data
July 6, 2025 / nimacimab obesity treatment / CB1 receptor antibody / Skye Bioscience weight loss / GLP-1 combination therapy / peripheral CB1 inhibition
Skye Bioscience’s nimacimab, a peripherally acting CB1 receptor antibody, shows promise in promoting weight loss without central nervous system side effects. Phase 2a trial results, including combination with GLP-1 therapy, are expected by late 2025.
AI Unlocks Hidden Connections Between Gut Bacteria and Human Health
July 4, 2025 / gut microbiome AI / personalized medicine microbiome / bacterial metabolites health / VBayesMM gut bacteria / microbiome-based therapy
University of Tokyo researchers developed VBayesMM, an AI tool that maps gut bacteria to health-related metabolites. This breakthrough may enable personalized treatments for conditions like obesity and sleep apnea by targeting specific microbial-metabolite interactions.
Lanifibranor reduces abnormalities in liver blood vessel cells: Study
July 7, 2025 / lanifibranor MASH treatment / liver fibrosis therapy / LSEC capillarization reversal / fatty liver disease drug / PPAR agonist liver
Lanifibranor, an oral PPAR agonist, reduced liver sinusoidal endothelial cell abnormalities in MASH patients, suggesting it may prevent fibrosis progression and cirrhosis by improving liver vascular health. Phase 3 data are expected in late 2025.
Influence of lifestyle risk factors and genetic predisposition on metabolic syndrome risk in Korean adults
July 5, 2025 / ‘metabolic syndrome risk / genetic predisposition MetS / lifestyle factors MetS / polygenic risk score / Korean adult health
Both genetic predisposition and unhealthy lifestyle factors significantly increase metabolic syndrome (MetS) risk in Korean adults. However, a healthy lifestyle can substantially reduce MetS risk—even among those with high genetic susceptibility.
The Impact of Semaglutide on Metabolic Syndrome: A Case Report
July 3, 2025 / semaglutide metabolic syndrome / GLP-1 receptor agonist / type 2 diabetes management / lipid profile improvement / renal protection diabetes
In a 44-year-old male with metabolic syndrome, switching from sitagliptin to semaglutide led to significant improvements in glycemic control, lipid profile, renal markers, and liver enzymes—highlighting semaglutide’s broad metabolic and organ-protective benefits.
Amino acid metabolism in breast cancer as a driver of disease and therapeutic target
July 7, 2025 / breast cancer metabolism / amino acid pathways / glutamine dependency TNBC / metabolic therapy targets / precision oncology breast cancer
Altered amino acid metabolism supports breast cancer progression and therapy resistance. Subtype-specific dependencies on glutamine, serine, arginine, and tryptophan reveal metabolic vulnerabilities that offer opportunities for targeted therapies, diagnostics, and precision medicine approaches in breast cancer treatment.
Damage from smoke and respiratory viruses mitigated in mice via a common signaling pathway
July 2, 2025 / Desert hedgehog signaling / lung tissue regeneration / neuroendocrine cell repair / airway viral damage / metabolic syndrome therapy
Stanford researchers identified that Desert hedgehog signaling from rare lung neuroendocrine cells activates tissue repair after smoke or viral damage. This pathway also protects pancreatic beta cells, offering potential therapeutic targets for respiratory illness and metabolic syndrome.
These warning symptoms on your hands can indicate fatty liver syndrome
July 7, 2025 / fatty liver symptoms / hand signs liver disease / nonalcoholic fatty liver / palmar erythema NAFLD / early liver damage clues
Early signs of fatty liver disease may appear on the hands as redness, itching, dryness, or spider veins. These skin changes reflect underlying metabolic dysfunction and warrant timely evaluation to prevent progression to liver fibrosis or cirrhosis.